Pharmaceuticals and Biotechnology Co-promotion and Co-marketing Partnering Trends Report 2024: Analysis of Deals Signed by the World's Leading Life Science Companies Signed Since 2016

News provided by

Mar 07, 2024, 11:15 ET

DUBLIN, March 7, 2024 /PRNewswire/ -- The "Co-promotion and Co-marketing in Pharmaceuticals and Biotechnology 2016-2024" report has been added to ResearchAndMarkets.com's offering.

Co-promotion and Co-marketing Deals in Pharmaceuticals and Biotechnology provides a detailed understanding and analysis of how and why companies enter co-promotion and co-marketing deals.

Fully revised and updated, the report provides details of co-promotion and co-marketing deals from 2016 to 2024, the report provides access to co-promotion and co-marketing deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of co-promotion and co-marketing deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual co-promotion and co-marketing contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview and analysis of the trends in co-promotion and co-marketing as well as a discussion on the merits of the type of deal. Chapter 3 provides an overview of the structure of co-promotion and co-marketing deals.

Chapter 4 provides a review of the leading co-promotion and co-marketing deals since 2016. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database. Chapter 5 provides a comprehensive listing of the top 25 most active co-promotion and co-marketing dealmaker companies. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand.

Chapter 6 provides a comprehensive and detailed review of co-promotion and co-marketing deals organized by company A-Z, therapy, technology and industry type signed and announced since 2016 where a contract document is available. Contract documents provide an indepth insight into the actual deal terms agreed between the parties with respect to the co-promotion and co-marketing deal.

The deal directory includes a comprehensive listing of all co-promotion and co-marketing deals announced since 2016. Each listing is organized as a deal directory by company A-Z, therapeutic area and technology type. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.

The report also includes numerous table and figures that illustrate the trends and activities in co-promotion and co-marketing dealmaking since 2016. In conclusion, this report provides everything a prospective dealmaker needs to know about co-promotion and co-marketing alliances.

Co-promotion and Co-marketing Deals in Pharmaceuticals and Biotechnology provides the reader with the following key benefits:

Understand deal trends since 2016
Browse co-promotion and co-marketing deals
Benchmark analysis - identify market value of transactions
Financials terms
Directory of deals by company A-Z, therapy focus and technology type
Leading deals by value
Most active dealmakers
Identify assets and deal terms for each transaction
Access contract documents - insights into deal structures
Due diligence - assess suitability of your proposed deal terms for partner companies
Save hundreds of hours of research time

Co-promotion and Co-marketing Deals in Pharmaceuticals and Biotechnology includes:

Trends in co-promotion and co-marketing dealmaking in the biopharma industry
Overview of co-promotion and co-marketing deal structure
Directory of co-promotion and co-marketing deal records covering pharmaceutical and biotechnology
The leading co-promotion and co-marketing deals by value
Most active co-promotion and co-marketing dealmakers
The leading co-promotion and co-marketing partnering resources

Analyzing contract agreements allows due diligence of:

What are the rights granted or optioned?
What rights are granted by the agreement?
What exclusivity is granted?
What is the payment structure for the deal?
How are sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are intellectual property rights handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in co-promotion and co-marketing dealmaking
2.1. Introduction
2.2. Definition of co-promotion and co-marketing deals
2.3. Trends in co-promotion and co-marketing deals since 2016
2.3.1. Co-promotion and co-marketing dealmaking by year, 2016-2024
2.3.2. Co-promotion and co-marketing dealmaking by phase of development, 2016-2024
2.3.3. Co-promotion and co-marketing dealmaking by industry sector, 2016-2024
2.3.4. Co-promotion and co-marketing dealmaking by therapy area, 2016-2024
2.3.5. Co-promotion and co-marketing dealmaking by technology type, 2016-2024
2.3.6. Co-promotion and co-marketing dealmaking by most active company, 2016-2024
2.4. Reasons for entering into co-promotion and co-marketing partnering deals
2.5. The future of co-promotion and co-marketing deals

Chapter 3 - Overview of co-promotion and co-marketing deal structure
3.1. Introduction
3.2. Co-promotion and co-marketing agreement structure

Chapter 4 - Leading co-promotion and co-marketing deals
4.1. Introduction
4.2. Top co-promotion and co-marketing deals by value

Chapter 5 - Top 25 most active co-promotion and co-marketing dealmakers
5.1. Introduction
5.2. Top 25 most active co-promotion and co-marketing dealmakers

Chapter 6 - Co-promotion and co-marketing deals including contracts directory
6.1. Introduction
6.2. Co-promotion and co-marketing deals with contracts 2016-2024

Deal directory

Deal directory - Co-promotion and co-marketing dealmaking by companies A-Z
Deal directory - Co-promotion and co-marketing dealmaking by therapy area
Deal directory - Co-promotion and co-marketing dealmaking by technology type

Some of the companies featured

3D Medicines
4D Molecular Therapeutics
Abbvie
AbCellera Biologics
ALK-Abello
Allegis Pharmaceuticals
Allergan
Bausch & Lomb
Baxalta
Bayer
Beam Therapeutics
BeiGene
Beijing Minhai Biotechnology
Belharra Therapeutics
Belintra
Berlin Chemie
BioAge Labs
Biogen
Biognosys
Biological Industries
BioNano Genomics
BioNTech
Cipher Pharmaceuticals
Concordia Pharmaceuticals
CRISPR Therapeutics
CrossLink Bioscience
CSL
Dova Pharmaceuticals
Dovetail Genomics
DualityBio
Eagle Genomics
Eagle Pharmaceuticals
EA Pharma
Eli Lilly
Empatica
Enterome Bioscience
Epizyme
Eton Pharmaceuticals
Exact Sciences
Fabric Genomics
Gilead Sciences
Glenmark Pharmaceuticals
Goldfinch Bio
GSK
GT Research
H3 Biomedicine
Halyard Health
Hanmi Pharmaceutical
Harbin Pharmaceutical Group
HD Biosciences
Iconic Therapeutics
Idorsia
IGM Biosciences
Illumina
Immatics Biotechnologies
Immunicon
ImmunityBio
Ionis Pharmaceuticals
Ironwood Pharmaceuticals
iTeos Therapeutics
Janssen Biotech
Janssen Pharmaceuticals
Jiangsu Alphamab
Konica Minolta
Kowa Pharmaceuticals America
KSQ Therapeutics
Kyorin Pharmaceutical
Kyowa Hakko Kirin
Kyverna Therapeutics
Luqa Pharmaceuticals
Luxcel Biosciences
Lygos
Macrogenics
Manchester BIOGEL
MannKind Biopharmaceuticals
Medicines360
MedImmune
Medovate
MEI Pharma
Menarini
Merck and Co
Merck KGaA
Mersana Therapeutics
Mesoblast
Metagenomi
Metavant
Microsoft
Nkarta Therapeutics
Novartis
Novo Nordisk
nRichDX
Numab
Otonomy
Otsuka
Oxford BioMedica
Pacira Biosciences
Paragon Bioservices
Pfizer
Phil
Prothena
Provention Bio
PSI (Population Services International)
Purdue Pharma
Pure Pharmaceuticals
QED Therapeutics
Qiagen
Quanta
Radius Health
Rainbow Scientific
Rakuten Medical
Recludix Pharma
RedHill Biopharma
RefleXion Medical
Regeneron Pharmaceuticals
Regenxbio
Relay Therapeutics
Repare Therapeutics
Resonant Specific Technologies
Revolution Medicines
Rigel Pharmaceuticals
Roche
Sanofi
Seren Pharmaceuticals
Seres Therapeutics
Shimadzu
Shionogi
Silicon Biosystems
Simcere Pharmaceuticals
Sirtex Medical
SK Biopharmaceuticals
Solid Biosciences
Sonoma BioTherapeutics
Sosei
SparingVision
Stealth BioTherapeutics
Stoke Therapeutics
StrideBio
Tango Therapeutics
Teijin
Telix Pharmaceuticals
Terumo Blood and Cell Technologies
Tetraphase Pharmaceuticals
Teva Pharmaceutical Industries
Theravance
Thermo Fisher Scientific
Tilak Healthcare
Tilray
Titan Pharmaceuticals
Tolmar
Urovant Sciences
US WorldMeds
Verity Pharmaceuticals
Vertex Pharmaceuticals
Vertice Pharma
Vifor Pharma
Voyager Therapeutics
WAVE Life Sciences
Xellia Pharmaceuticals
Xencor
ZAI Laboratory
Zymeworks

For more information about this report visit https://www.researchandmarkets.com/r/dw3ldi

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

SOURCE Research and Markets